Ameriprise’s CytomX Therapeutics CTMX Stock Holding History

Ameriprise’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$53.3K	Sell	14,202 -50,813	-78%	-$194K	﹤0.01%	4059
2026 Q1	$306K	Sell	65,015 -164,584	-72%	-$835K	﹤0.01%	3758
2025 Q4	$989K	Buy	229,599 +71,270	+45%	+$271K	﹤0.01%	3345
2025 Q3	$505K	Buy	+158,329	New	+$357K	﹤0.01%	3620
2022 Q4	–	Sell	-74,853	Closed	-$109K	–	3979
2022 Q3	$109K	Buy	+74,853	New	+$115K	﹤0.01%	3812
2018 Q3	–	Sell	-51,852	Closed	-$1.19M	–	3733
2018 Q2	$1.19M	Sell	51,852 -941	-2%	-$24K	﹤0.01%	2953
2018 Q1	$1.5M	Buy	+52,793	New	+$1.51M	﹤0.01%	2802

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Ameriprise's CTMX Position: Q2 2026 in Review

Ameriprise reduced its CytomX Therapeutics (CTMX) stake by 78% in Q2 2026, selling an estimated $194K and leaving 14,202 shares worth $53.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4059.

Ameriprise first reported a position in CTMX in Q1 2018 and has held it in 7 quarters since. The position peaked at $1.5M in Q1 2018. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

Ameriprise held 14,202 shares of CytomX Therapeutics worth $53.3K as of Q2 2026.
Ameriprise sold 50,813 CytomX Therapeutics shares in Q2 2026, an estimated $194K.
CytomX Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #4059 holding.
Ameriprise first reported a position in CytomX Therapeutics in Q1 2018 and has held it in 7 quarters since.
Ameriprise's CytomX Therapeutics position peaked at $1.5M in Q1 2018.
179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.